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366Urinary Calcium Excretion and Risk
of Chronic Kidney Disease in the
General Population
Jacob M. Taylor1, Lyanne M. Kieneker1, Martin H. de Borst1, Sipke T. Visser2, Ido P. Kema3,
Stephan J.L. Bakker1 and Ron T. Gansevoort1; for the PREVEND Study Group
1Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands;
2Department of Pharmacoepidemiology and Pharmacoeconomics, University of Groningen, University Medical Center Gro-
ningen, Groningen, the Netherlands; and 3Department of Laboratory Medicine, University of Groningen, University Medical
Center Groningen, Groningen, the NetherlandsIntroduction: High urinary calcium excretion (UCaE) has been shown to lead to accelerated renal function
decline in individuals with renal tubular diseases. It is not known whether this association also exists in the
general population. Therefore, we investigated whether high UCaE is associated with risk of developing
chronic kidney disease (CKD) in community-dwelling subjects.
Methods: Urine samples of 5491 subjects who were free of CKD at baseline and participated in the Pre-
vention of Renal and Vascular End-Stage Disease study (a prospective, observational, general population-
based cohort of Dutch men and women aged 28–75 years) were examined for UCaE. UCa concentration
was measured in two 24-hour urine samples at baseline (1997–1998) by indirect potentiometry. UCaE was
treated as a continuous variable and a categorical variable grouped according to sex-speciﬁc quintiles for
UCaE. UCaE was compared with de novo development of estimated glomerular ﬁltration rate <60 ml/min
per 1.73 m2 and/or albuminuria >30 mg/24 h.
Results: Baseline median UCaE was 4.13 mmol/24 h for men and 3.52 mmol/24 h for women. During a
median follow-up of 10.3 years, 899 subjects developed CKD. After multivariable adjustment, every 1
mmol/24 h higher baseline UCaE was associated with a 6% lower risk for incident CKD during follow-up
(hazard ratio: 0.94 [0.88–0.99], P ¼ 0.02). The association was shown to be signiﬁcantly nonlinear, with
highest risk of CKD in the lowest quintile for UCaE (hazard ratio: 1.28 [0.97–1.68], P ¼ 0.09). There was no
association between UCaE and mortality or cardiovascular health during follow-up, suggesting that this
association was not a reﬂection of poor nutritional intake due to bad health.
Discussion: These ﬁndings indicate that high UCaE does not increase risk of CKD, but rather that low UCaE
may be harmful.
Kidney Int Rep (2017) 2, 366–379; http://dx.doi.org/10.1016/j.ekir.2016.12.007
KEYWORDS: calcium; chronic kidney disease; hypercalciuria; nutrition
ª 2016 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).C alcium and vitamin D are essential nutrients forhuman health, playing a pivotal role in normal
bone mineralization. Yet, data from Dutch and Amer-
ican cohorts show that less than 50% of adults meet
their daily recommended intake for calcium and are
assumed to be at risk for bone fractures.1–3 To meet
these recommendations, a substantial portion of
the population must increase calcium intake through
dietary interventions, such as by increasing the intake
of dairy products, or by being prescribed daily calciumspondence: Jacob M Taylor, University Medical Center
ngen, University of Groningen, PO box 30.001, 9700 RB
ngen, the Netherlands. E-mail: j.m.taylor@umcg.nl
ved 23 November 2016; revised 19 December 2016; accepted
cember 2016; published online 31 December 2016supplements. Recently, however, investigators have
questioned whether increasing the intake of calcium is
beneﬁcial, because higher intakes of calcium were not
associated with a reduction in bone fractures.4 The
promotion of higher intakes of calcium has also come
under scrutiny because this will likely lead to higher
high urinary calcium excretion (UCaE) and kidneys
may be susceptible to damage from high UCaE.
It has been shown that speciﬁc renal tubular diseases
that result in hypercalciuria lead to nephrocalcinosis
and accelerated renal function loss. For instance, 30%
to 80% of males suffering from Dent’s disease develop
chronic kidney disease (CKD) between 30 and 50 years
of age, and familial hypomagnesemia with hyper-
calciuria results in CKD by age 30 in 50% to 73% of
cases.5–8 These ﬁndings suggest that elevated levels ofKidney International Reports (2017) 2, 366–379
JM Taylor et al.: Urinary Calcium Excretion and CKD CLINICAL RESEARCHUCaE may have deleterious renal effects. Cohort studies
that investigated the impact of UCaE, such as the
Nurses’ Health Study, have focused on the association
between UCaE and kidney stones, leaving unknown
whether high UCaE affects long-term kidney function
in community-dwelling subjects.9 Therefore, we
investigated the association between high UCaE and
risk of developing CKD in a general population cohort.
MATERIALS AND METHODS
Study Design and Population
The Prevention of Renal and Vascular End-Stage Dis-
ease (PREVEND) study is designed to prospectively
investigate the natural course of increased levels of
urinary albumin excretion (UAE) and its relation with
renal and cardiovascular outcome in a large cohort
drawn from the general population. Details of this
study have been described elsewhere.10 In brief, from
1997 to 1998, all inhabitants of Groningen (the
Netherlands), aged 28 to 75 years (n ¼ 85,421), were
sent a short questionnaire on demographics and renal
and cardiovascular morbidity and a vial to collect a ﬁrst
morning void urine sample. Altogether, 40,856 people
(48%) responded and their urinary albumin concen-
tration was assessed. Of these people, 9966 had a uri-
nary albumin concentration of $10 mg/l. After
exclusion of pregnant women and subjects with type 1
diabetes mellitus, 7768 subjects were invited to
participate, of whom 6000 consented and were
enrolled. In addition, of the 40,856 responders, there
were 30,890 people with a urinary albumin
concentration <10 mg/l. After exclusion of pregnant
women and subjects with type 1 diabetes mellitus, a
randomly selected group with a urinary albumin con-
centration of <10 mg/l (n ¼ 3394) was invited to
participate in the cohort, of whom 2592 consented and
were enrolled. These 8592 individuals form the PRE-
VEND cohort and completed an extensive examination
in 1997 and 1998 (baseline). A total of 6894 participants
completed a second examination between 2001 and
2003, 5863 a third examination between 2003 and 2006,
5078 a fourth examination between 2006 and 2008, and
4600 a ﬁfth examination between 2008 and 2011.
For the present analyses, we excluded subjects with
CKD (n ¼ 1397), unknown CKD status (n ¼ 501), renal
disease requiring dialysis (n ¼ 11), and missing values
of UCaE (n ¼ 5) at baseline. In addition, those with no
follow-up data available for assessment of CKD status
(n ¼ 1187) were also excluded. This left 5491 partici-
pants to be included in the analysis (Figure 1). The
PREVEND study was approved by the medical ethics
committee of the University Medical Center Groningen.
Written informed consent was obtained from all
participants.Kidney International Reports (2017) 2, 366–379Data Collection
The procedures at each examination in the PREVEND
study have been described in detail previously.11 In
brief, each examination included 2 visits to an outpa-
tient clinic separated by a maximum of 3 weeks. Before
the ﬁrst visit, all participants completed a self-
administered questionnaire regarding demographics,
cardiovascular and renal disease history, smoking
habits, alcohol consumption, and medication use.
Information on medication use was combined with
information from community pharmacies. During the
ﬁrst visit, participants’ height and weight were
assessed. During each examination and during each
visit, blood pressure was measured on the right arm,
every minute for 10 and 8 minutes, respectively, by an
automatic Dinamap XL Model 9300 series device
(Johnson-Johnson Medical, Tampa, FL). The mean of
the last 2 recordings from each of the 2 visits was used.
In the week before the second visit, subjects collected 2
consecutive 24-hour specimens after thorough oral and
written instruction. The participants were asked to
avoid heavy exercise as much as possible during the
urine collection and to postpone the urine collection in
case of urinary tract infection, menstruation, or fever.
The collected urine was stored in a cold environment
(4C) for a maximum of 4 days before handing in the
urine collections. Aliquots of these urine specimens
were then stored at 20C. Furthermore, fasting blood
samples were obtained at the second visit and were
stored at 80C.
Assessment of Urinary Calcium Excretion
Urinary calcium concentration was determined by in-
direct potentiometry with a MEGA clinical chemistry
analyzer (Merck, Darmstadt, Germany).12 Urinary cal-
cium concentration was multiplied by urine volume to
obtain UCaE (in mmol per 24 hours). The average value
of the paired 24-hour collections was calculated and
used for analysis.
Ascertainment of Incident CKD, Cardiovascular
Events, and Mortality
The primary outcome of incident CKD was deﬁned
as reaching an estimated glomerular ﬁltration rate
(eGFR) of <60 ml/min per 1.73 m2 and/or a UAE of
>30 mg/24 h de novo. GFR was estimated with the
combined creatinine cystatin C-based Chronic Kidney
Disease Epidemiology (CKD-EPI) Collaboration equation
from 2012.13
Serum creatinine concentration was measured by an
isotope dilution mass spectrometry traceable enzymatic
method on a Roche Modular analyzer (Roche
Diagnostics, Mannheim, Germany). Serum cystatin C
concentration was measured by an immunoassay367
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Figure 1. Flow chart of study design and exclusion criteria for analyses. CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate;
UAC, urinary albumin concentration.
CLINICAL RESEARCH JM Taylor et al.: Urinary Calcium Excretion and CKD(Gentian AS, Moss, Norway) on a Modular analyzer
(Roche Diagnostics) calibrated directly using the stan-
dard supplied by the manufacturer (traceable to the
International Federation of Clinical Chemistry Working
Group for Standardization of Serum Cystatin C).14
Urinary albumin concentration was measured in ali-
quots from the 24-hour urine collections by nephe-
lometry (Dade Behring Diagnostic, Marburg, Germany)
with a threshold of 2.3 mg/l. Urinary albumin con-
centration was multiplied by 24-hour urine volume to
obtain UAE (in mg/24 h). The two 24-hour UAE values
of each subject per examination were averaged and
used in the analysis.
Data on mortality and incident fatal and nonfatal
cardiovascular events during follow-up were examined
to investigate whether low UCaE may reﬂect poor368dietary intake due to impaired general health. Data on
mortality and fatal cardiovascular events were received
through the municipal register, whereas data on
nonfatal cardiovascular events were obtained from
Prismant, the Dutch national registry of hospital
discharge diagnoses. Cardiovascular events were coded
according to the International Classiﬁcation of Diseases,
Ninth Revision, and consisted of cardiac events (code
410, 411, 414, 36.0), cerebrovascular events (code 430–
434), and vascular interventions, including percuta-
neous transluminal angioplasty and bypass grafting of
aorta and peripheral vessels.
Assessment of Covariates
Smoking status was self-reported as never smoker,
former smoker, or current smoker. Alcohol intake wasKidney International Reports (2017) 2, 366–379
JM Taylor et al.: Urinary Calcium Excretion and CKD CLINICAL RESEARCHself-reported as no/rarely, 1–4 drinks/mo, 2–6 drinks/
wk, 1–3 drinks/d, or $4 drinks/d. Parental history of
CKD was deﬁned as having a ﬁrst-degree relative
who had a renal disease requiring dialysis for >6
weeks. Hypertension was deﬁned as systolic
blood pressure of $140 mm Hg, a diastolic blood
pressure of $90 mm Hg, or the use of antihypertensive
agents as previously described.15,16 Urinary sodium,
potassium, magnesium, urea and circulating levels
of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D,
calcium, phosphorus, parathyroid hormone (PTH),
magnesium, total cholesterol, high-density lipoprotein
cholesterol, triglycerides, and glucose were determined
as previously described.12,17–20 Hypercholesterolemia
was deﬁned as having a total cholesterol >6.2 mmol/l
without a history of myocardial infarction, a total
cholesterol >5.2 mmol/l with a history of myocardial
infarction, or use of a lipid lowering drug. Diabetes was
deﬁned as a fasting plasma glucose $7.0 mmol/l (>126
mg/dl) or the use of glucose-lowering drugs.21 Infor-
mation on calcium and vitamin D supplements, thiazide
and loop diuretics, and bisphosphonates was obtained
from the IADB.nl database, a database that contains
pharmacy-dispensing data from community pharmacies
in the northern part of the Netherlands.22
Statistical Analyses
Baseline characteristics are presented according to sex-
speciﬁc quintiles of UCaE. Ranges for the quintiles
remained the same during sensitivity analyses to allow
for ease comparing results. Continuous data are pre-
sented as mean  SD or as median (interquartile range
[IQR]) in the case of a skewed distribution. Categorical
data are presented as percentages. Linear-by-linear
associations were determined by the c2 test for cate-
gorical variables and linear regression for continuous
variables.
UCaE was analyzed as a continuous variable and in
sex-speciﬁc quintiles. To study the prospective asso-
ciation between UCaE and risk of developing CKD, Cox
proportional hazards regression analyses were used to
calculate hazard ratios (HRs) and 95% conﬁdence in-
tervals. Nonlinearity was tested by using the likelihood
ratio test, comparing nested models with linear and
cubic spline terms.
We ﬁrst calculated HRs (95% conﬁdence intervals)
for the crude model. Second, we adjusted for body size
and nonmodiﬁable factors associated with risk of kid-
ney dysfunction, including age, sex, height, weight,
race, and baseline eGFR and lnUAE. Third, we
adjusted for renal disease risk factors, including
smoking, alcohol, hypertension, diabetes, parental
history of CKD, and hypercholesterolemia. Fourth, we
adjusted for plasma markers and supplement/Kidney International Reports (2017) 2, 366–379medication usage that may affect calcium uptake and
excretion, including plasma magnesium, calcium,
phosphorus, PTH, 1,25 dihydroxyvitamin D, albumin,
use of loop diuretics, thiazide diuretics, calcium sup-
plements, vitamin D supplements, and bisphospho-
nates. Finally, we additionally adjusted for dietary
factors potentially associated with risk of CKD and
UCaE, including urinary sodium, potassium, urea, and
magnesium excretion. In secondary analyses, CKD
incidence was deﬁned by either impaired eGFR or
albuminuria alone. We also evaluated potential effect
modiﬁcation by sex, plasma calcium, PTH, 25-
hydroxyvitamin D, and 1,25-dihydroxyvitamin D, by
ﬁtting models containing both the main effects and
their cross-product terms.
Several sensitivity analyses were performed to
examine the robustness of the associations between
UCaE and risk of CKD. First, we excluded subjects at
baseline with an eGFR <66 ml/min per 1.73 m2 (instead
of <60) and/or a UAE >25 mg/24 h (instead of >30) to
assure a more pronounced decline in kidney function
to deﬁne the primary outcome of incident CKD. Second,
we analyzed the data excluding subjects with potential
inadequate 24-hour urine collections. We deﬁned po-
tential inadequate 24-hour urine collections (i.e., over
or under collection) as the upper and lower 2.5% of the
difference between the estimated and measured volume
of a subject’s 24-hour urine sample. The estimated 24-
hour urine volume was derived from the formula:
Creatinine clearance ¼ ([urine creatinine]  24-hour
urine volume)/[serum creatinine]), where creatinine
clearance was estimated using the Cockcroft-Gault
formula.23 Third, we addressed the oversampling of
subjects with higher urinary albumin concentrations
by analyzing the data in a subset of subjects from the
cohort that are representative of the Netherlands pop-
ulation. This subset included all subjects with a uri-
nary albumin concentration of <10 mg/l who
completed the ﬁrst screening (n ¼ 2592) with the
addition of the “oversampled” subjects whose urinary
albumin concentration was$10 mg/l by proportionally
taking a computer-generated random subset (n ¼ 840).
After applying the same exclusion criteria as in the
primary analysis, 929 subjects were excluded leaving a
cohort of 2503 subjects to be analyzed as an unbiased
sample. Fourth, the association between UCaE and
decline in eGFR per year was also examined to identify
CKD risk. Linear mixed model analysis was performed
with the repeated measures of eGFR as the outcome and
a random effect for time, to allow for individual de-
viations to the overall population slope. Individuals
with at least 2 observations were included in the
analysis (without excluding individuals with CKD at
baseline). Betas are expressed per 1 SD increase for369
CLINICAL RESEARCH JM Taylor et al.: Urinary Calcium Excretion and CKDcontinuous variables and versus the reference category
for dichotomous variables. Fifth, the same group was
divided into fast progressors and slow progressors to
CKD, and the association between UCaE and risk of
being a fast progressor was examined using a logistic
regression analysis. Fast progressors were deﬁned as
the 20% of individuals with the steepest decline in
eGFR per year in the cohort. Finally, in this group,
we also analyzed the association between UCaE and
risk of having an eGFR decline $25% during
follow-up.
In addition, to study the prospective association
between UCaE and risk of all-cause mortality and fatal
and nonfatal cardiovascular events, Cox proportional
hazards regression analyses were used to calculate HRs
and 95% conﬁdence intervals. Nonlinearity was tested
by using the likelihood ratio test, comparing nested
models with linear and cubic spline terms. The same
covariates were adjusted for in the models as was done
when examining risk of developing CKD, with the
addition of history of cardiovascular events that was
added to models 2–4.
All P values are 2-tailed. A P value <0.05 was
considered statistically signiﬁcant. All analyses were
conducted with the use of the statistical package IBM
SPSS (version 22; SPSS, Chicago, IL) and Rstudio
(version 0.99.491; Rstudio, Boston, MA).
RESULTS
Baseline Demographic, Clinical, and Laboratory
Characteristics
Median UCaE at baseline was 3.82 mmol/24 h (IQR:
2.64–5.12 mmol/24 h), with a higher excretion in men
(median: 4.13 mmol/24 h; IQR: 2.93–5.49 mmol/24 h)
than in women (median: 3.52 mmol/24 h; IQR: 2.40–
4.81 mmol/24 h). Baseline characteristics are therefore
shown according to sex-speciﬁc quintiles of UCaE
(Table 1). Subjects with a higher UCaE at baseline were
older, more likely to be hypertensive, hypercholester-
olemic, diabetic, and have a higher weight, height, and
body mass index. These same individuals were also less
likely to be current smokers, consume no alcohol, and
be on thiazide diuretics. In addition, subjects with
higher UCaE had higher plasma calcium, 25-
hydroxyvitamin D and 1,25-dihydroxyvitamin D, a
lower plasma phosphorus, and higher urinary potas-
sium, sodium, magnesium, urea, creatinine, and albu-
min excretion.
Risk of CKD During Follow-up
During a median follow-up of 10.3 years (IQR: 6.2–11.4
years), a total of 899 incident CKD events (deﬁned as an
eGFR of <60 ml/min per 1.73 m2 and/or a UAE >30
mg/24 h) were identiﬁed. Examination of linear trends370showed that, after adjustment for age, sex, height,
weight, race, and baseline eGFR and lnUAE, every 1
mmol/24 h higher baseline UCaE was associated with an
8% lower risk for incident CKD during follow-up (HR:
0.92 [0.89–0.95], P < 0.001) (Table 2). These ﬁndings
persisted after additional adjustment for renal risk
factors (model 2), plasma markers, and supplement/
medication usage that may affect calcium uptake and
excretion (model 3) and dietary factors potentially
associated with risk of CKD (model 4) (HR: 0.94 [0.88–
0.99], P ¼ 0.02) (Table 2).
The association between UCaE and CKD was
signiﬁcantly nonlinear (P # 0.01 in all models), and
this was conﬁrmed visually by the multivariable-
adjusted spline curve (Table 2, Figure 2). Thus, we
conducted further analyses using sex-speciﬁc quintiles
for UCaE to allow investigation of nonlinear associa-
tions. In these analyses, no increased risk of CKD was
observed in the higher UCaE range. However, sur-
prisingly, the highest risk was observed in the lowest
quintile for UCaE (Table 2). After adjustment for age,
sex, height, weight, race, and baseline eGFR and
lnUAE, individuals in the lowest quintile for UCaE had
a signiﬁcantly increased risk of developing CKD (HR:
1.41 [1.15–1.73], P ¼ 0.001). This increased risk
remained in the lowest quintile, even after extensive
adjustment (model 4, HR: 1.28 [0.97–1.68], P ¼ 0.09).
No effect modiﬁcation by sex, plasma calcium, PTH,
25-hydroxyvitamin D, and 1,25-dihydroxyvitamin D
was detected in the association between UCaE and CKD
(P > 0.05).
Secondary Analyses of CKD Using Only eGFR or
UAE to Deﬁne Endpoint
In a secondary analysis, incident CKD was deﬁned
as reaching an eGFR <60 ml/min per 1.73 m2. Again,
a signiﬁcant association between UCaE and risk of
incident CKD during follow-up was observed (model
1, HR: 0.89 [0.83–0.95], P ¼ 0.001). This association
remained signiﬁcant after adjustment for all other
variables in the ﬁnal model (HR: 0.89 [0.80–0.99], P ¼
0.03) (Table 2). In a separate secondary analysis,
incident CKD was deﬁned as reaching a UAE >30 mg/
24 h. The association between UCaE and CKD was
signiﬁcantly nonlinear, and was conﬁrmed visually
by the multivariable-adjusted spline curve (P < 0.05
in all models) (Table 2, Figure 2). After adjustment for
age, sex, height, weight, race, and baseline eGFR and
lnUAE, individuals in the lowest quintile for UCaE
had a signiﬁcantly increased risk of developing
CKD (HR: 1.40 [1.11–1.78], P ¼ 0.01), a trend
that remained in the lowest quintile through the
rest of the models (model 4, HR: 1.39 [0.99–1.93],
P ¼ 0.05).Kidney International Reports (2017) 2, 366–379
Table 1. Baseline characteristics according to quintiles of urinary calcium excretion of 5491 subjects of the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study
Variables N Overall
Sex-speciﬁc quintiles of urinary calcium excretion, mmol/24 h
Ptrend lineara
_ <2.65 2.65--3.67 3.68--4.58 4.59--5.80 >5.80
\ <2.16 2.16--3.08 3.09--4.00 4.01--5.14 >5.14
Participants, N 5491  1098 1098 1101 1097 1097
Women, % 5491 52.6 52.6 52.6 52.7 52.6 52.6 0.98
Age, yr 5491 48.3  11.7 47.9  12.7 47.9  12.2 48.2  11.7 48.2  11.2 49.4  10.8 0.001
Race, whites, % 5454 95.9 91.8 95.4 96.7 97.3 98.3 <0.001
Parental history of CKD, % 5491 1.5 1.7 1.4 1.1 1.7 1.5 1.00
Smoking status, current, % 5491 31.8 34.7 33.1 34.1 29.9 27.3 <0.001
Alcohol consumption, none, % 5491 26.7 27.4 25.5 21.3 22.3 20.2 <0.001
Weight, kg 5434 77.1  13.5 75.5  13.3 75.7  13.0 75.8  12.6 78.1  13.7 80.5  14.4 <0.001
Length, cm 5436 173.1  9.5 172.4  9.6 172.7  9.5 173.0  9.0 173.5  9.7 174.1  9.4 <0.001
BMI, kg/m2 5434 25.7  4.0 25.4  4.1 25.4  3.8 25.3 3.7 25.9  4.0 26.5  4.1 <0.001
Systolic blood pressure, mm Hg 5490 126  18 124  18 125  19 126  18 126  17 128  17 <0.001
Diastolic blood pressure, mm Hg 5490 73  9 72  9 72  9 73  9 73  9 74  9 <0.001
Antihypertensive use, % 5491 11.6 13.9 11.2 10.7 11.0 11.1 0.06
Hypertension, % 5412 26.7 25.8 24.1 26.2 27.7 29.6 0.008
Total cholesterol, mmol/l 5469 5.58  1.11 5.49  1.11 5.55  1.12 5.58  1.06 5.58  1.17 5.73  1.08 <0.001
HDL cholesterol, mmol/l 5436 1.35  0.40 1.32  0.40 1.35  0.39 1.36  0.40 1.35  0.39 1.37  0.41 0.01
Triglycerides, mmol/l 5436 1.11 (0.81–1.60) 1.10 (0.81–1.58) 1.10 (0.80–1.55) 1.10 (0.81–1.58) 1.08 (0.80–1.54) 1.17 (0.85–1.69) 0.01
Lipid lowering drug use, % 5491 5.1 5.4 5.2 5.0 4.9 5.1 0.70
Hypercholesterolemia, % 5470 29.8 27.9 29.0 29.8 29.1 33.2 0.01
Glucose, mmol/l 5476 4.7  0.9 4.7  0.8 4.7  0.7 4.7  0.8 4.8  0.8 4.9  1.3 <0.001
Antidiabetic drug use, % 5473 1.0 0.6 0.6 1.4 1.1 1.5 0.03
Diabetes, % 5456 2.0 1.3 1.2 1.9 2.2 3.3 <0.001
eGFR, ml/min per 1.73 m2 5491 97  15 96  16 97  15 98  15 98  14 98  14 <0.001
Plasma calcium, mmol/l 5130 2.28  0.08 2.27  0.08 2.27  0.08 2.28  0.08 2.28  0.08 2.28  0.09 0.02
Plasma magnesium, mmol/l 5136 0.81  0.06 0.81  0.06 0.81  0.07 0.81  0.06 0.81  0.05 0.81  0.06 0.08
Plasma phosphorus, mmol/l 5136 1.1  0.16 1.01  0.16 1.02  0.16 1.02  0.16 1.01  0.15 1.00  0.16 0.02
PTH, pmol/l 5301 3.62 (2.92–4.49) 3.84 (3.10–4.74) 3.62 (2.90–4.43) 3.52 (2.89–4.36) 3.49 (2.85–4.38) 3.67 (2.92–4.56) <0.001
25-Hydroxyvitamin D, nmol/l 5329 58  23 53  24 57  23 57  23 60  22 61  23 <0.001
1,25-Dihydroxyvitamin D, pmol/l 5324 145  47 136  45 141  43 143  45 150  47 157  52 <0.001
Plasma albumin, g/l 5136 45.9  2.6 45.7  2.6 45.7  2.6 46.0  2.4 45.9  2.5 45.9  2.6 0.01
Urinary excretion:
Calcium, mmol/24 h 5491 3.82 (2.64–5.12) 1.70 (1.27–2.06) 2.88 (2.64–3.13) 3.83 (3.50–4.11) 4.80 (4.45–5.12) 6.51 (5.92–7.51) <0.001
Potassium, mmol/24 h 5491 70.4 (57.3–84.9) 64.2 (51.1–78.6) 67.2 (53.5–81.4) 71.7 (58.2–85.3) 73.4 (60.8–87.0) 75.3 (62.4–89.7) <0.001
Sodium, mmol/24 h 5491 135 (105–169) 115 (88–146) 123 (96–156) 133 (107–164) 144 (117–177) 160 (131–197) <0.001
Magnesium, mmol/24 h 5463 3.80 (2.93–4.78) 2.78 (1.81–3.71) 3.37 (2.58–4.17) 3.83 (3.11–4.70) 4.19 (3.39–5.13) 4.69 (3.88–5.72) <0.001
Urea, mmol/24 h 5491 346 (283–418) 294 (237–358) 317 (263–392) 341 (290–407) 367 (311–439) 407 (341–475) <0.001
Creatinine, mmol/24 h 5471 11.8 (9.6–14.5) 10.7 (9.0–13.2) 11.4 (9.1–13.9) 11.7 (9.6–14.3) 12.3 (10.1–15.0) 12.8 (10.5–16.1) <0.001
Albumin, mg/24 h 5491 8.1 (5.9–12.1) 7.0 (5.2–11.0) 7.5 (5.6–11.1) 8.1 (6.0–12.3) 8.5 (6.2–12.0) 9.5 (7.0–14.1) <0.001
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372Sensitivity Analyses and Alternate Endpoints to
Deﬁne CKD
We also conducted several sensitivity analyses. First,
we removed individuals with an eGFR 60–66 ml/min
per 1.73 m2 and UAE 25–30 mg/24 h at baseline to
assure that the endpoint of incident CKD reﬂects a
more prominent decrease in eGFR and increase in
albuminuria. Compared with the initial ﬁndings, we
found similar HRs for CKD in the lowest quintiles of
UCaE in the ﬁnal models when deﬁned by the com-
bined eGFR and UAE endpoint and when assessing
CKD only by UAE (HR: 1.28 [0.94, 1.74], P ¼ 0.12 and
HR: 1.46 [1.03, 2.07], P ¼ 0.03, respectively). When
CKD was deﬁned only by eGFR, a similar linear asso-
ciation with the initial ﬁndings was observed in the
ﬁnal model (HR: 0.88 [0.79, 1.00], P ¼ 0.04)
(Supplementary Table S1). Second, when we accounted
for potential over- and undercollection of 24-hour
urine samples in the cohort, results were in accord
with the original ﬁndings (Supplementary Table S2).
Third, after accounting for the oversampling of
individuals with elevated UAE (>10 mg/l) due to the
study design, signiﬁcant nonlinear associations were
also observed between UCaE and risk of the combined
endpoint (P ¼ 0.03) and UAE endpoint (P ¼ 0.03). In
agreement with the initial ﬁndings, an increased risk of
CKD was observed in the lowest UCaE quintile for the
combined and UAE endpoint, but did not reach sta-
tistical signiﬁcance potentially due to loss of power
(n ¼ 2503 instead of n ¼ 5491). The association be-
tween UCaE and eGFR was consistent with the original
ﬁndings (HR: 0.83 [0.69–1.00], P ¼ 0.05) in this
sensitivity analysis (Supplementary Table S3). Fourth,
when examining the association between UCaE and
decrease in eGFR per year (without excluding in-
dividuals with CKD at baseline [n ¼ 6531]), after
adjustment for all covariates, having a higher UCaE
was associated with a steeper decline in eGFR during
follow-up (model 4, P < 0.001) (Table 3) (baseline
characteristics in Supplementary Table S4). We also
examined the association between UCaE and the risk of
being a fast progressor to CKD in the same group,
deﬁned as belonging to the 20% of individuals with
the steepest decline in eGFR per year during follow-up.
This sensitivity analysis demonstrated that for every 1
mmol/24 h increase in UCaE, the risk of being a fast
progressor was reduced by 8% (odds ratio: 0.92 [0.87–
0.97], P ¼ 0.003), further conﬁrming the initial ﬁnd-
ings (Table 4). In a ﬁnal sensitivity analysis, we
analyzed the association between UCaE and risk having
an eGFR decline $25% during follow-up. Again, there
was an inverse relationship between UCaE and risk
of kidney function decline (HR: 0.91 [0.84–0.99],
P ¼ 0.02) (Table 5).Kidney International Reports (2017) 2, 366–379
Table 2. Association between urinary calcium excretion and risk of chronic kidney disease in 5491 subjects of the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study
CKD deﬁnition Continuous urinary calcium excretion, per 1 mmol/24 h increment Ptrend lineara
Sex-speciﬁc quintiles of urinary calcium excretion, mmol/24 h
Ptrend nonlinearb
_ <2.65 2.65--3.67 3.68--4.58 4.59--5.80 >5.80
\ <2.16 2.16--3.08 3.09--4.00 4.01--5.14 >5.14
eGFR <60 ml/min per 1.73 m2 or UAE >30 mg/24 h
Person-years 48,648 9371 9609 9752 9969 9947
Number of events 899 213 180 166 155 185
Crude model 0.98 (0.95, 1.02) 0.28 1.34 (1.09, 1.64) 1.10 (0.89, 1.36) 1.00 (ref) 0.91 (0.73, 1.13) 1.09 (0.88, 1.34) 0.001
Model 1c 0.92 (0.89, 0.95) <0.001 1.41 (1.15, 1.73) 1.17 (0.95, 1.45) 1.00 (ref) 0.88 (0.70, 1.09) 0.86 (0.70, 1.07) 0.01
Model 2d 0.91 (0.88, 0.94) <0.001 1.45 (1.18, 1.79) 1.18 (0.95, 1.46) 1.00 (ref) 0.84 (0.67, 1.05) 0.85 (0.68, 1.05) 0.002
Model 3e 0.90 (0.86, 0.95) <0.001 1.38 (1.06, 1.80) 1.21 (0.93, 1.58) 1.00 (ref) 0.73 (0.55, 0.98) 0.80 (0.61, 1.06) 0.002
Model 4f 0.94 (0.88, 0.99) 0.02 1.28 (0.97, 1.68) 1.19 (0.91, 1.55) 1.00 (ref) 0.77 (0.57, 1.03) 0.88 (0.66, 1.17) 0.004
eGFR <60 ml/min per 1.73 m2
Person-years 51,938 10,003 10,191 10,381 10,595 10,768
Number of events 299 95 76 53 36 39
Crude model 0.79 (0.74, 0.85) <0.001 1.87 (1.34, 2.62) 1.47 (1.03, 2.08) 1.00 (ref) 0.66 (0.43, 1.01) 0.70 (0.47, 1.06) 0.34
Model 1c 0.89 (0.83, 0.95) 0.001 1.36 (0.97, 1.90) 1.37 (0.96, 1.95) 1.00 (ref) 0.82 (0.54, 1.26) 0.79 (0.52, 1.20) 0.85
Model 2d 0.89 (0.83, 0.96) 0.001 1.35 (0.96, 1.90) 1.31 (0.92, 1.88) 1.00 (ref) 0.76 (0.50, 1.17) 0.81 (0.53, 1.24) 0.72
Model 3e 0.83 (0.76, 0.91) <0.001 1.62 (1.06, 2.48) 1.54 (1.01, 2.36) 1.00 (ref) 0.89 (0.53, 1.48) 0.67 (0.39, 1.16) 0.48
Model 4f 0.89 (0.80, 0.99) 0.03 1.30 (0.82, 2.05) 1.46 (0.95, 2.24) 1.00 (ref) 0.95 (0.57, 1.59) 0.73 (0.42, 1.27) 0.90
UAE >30 mg/24 h
Person-years 52,209 10,169 10,386 10,523 10,588 10,543
Number of events 692 153 116 128 132 163
Crude model 1.05 (1.01, 1.09) 0.02 1.23 (0.97, 1.56) 0.92 (0.71, 1.18) 1.00 (ref) 1.02 (0.80, 1.30) 1.27 (1.00, 1.60) 0.02
Model 1c 0.94 (0.91, 0.98) 0.002 1.40 (1.11, 1.78) 1.03 (0.80, 1.32) 1.00 (ref) 0.96 (0.75, 1.23) 0.93 (0.74, 1.18) 0.02
Model 2d 0.93 (0.90, 0.97) 0.001 1.43 (1.12, 1.82) 1.03 (0.80, 1.33) 1.00 (ref) 0.92 (0.71, 1.18) 0.90 (0.71, 1.14) 0.01
Model 3e 0.94 (0.89, 0.99) 0.02 1.39 (1.02, 1.89) 0.97 (0.70, 1.36) 1.00 (ref) 0.78 (0.56, 1.10) 0.91 (0.66, 1.25) 0.004
Model 4f 0.96 (0.90, 1.02) 0.20 1.39 (0.99, 1.93) 0.98 (0.70, 1.37) 1.00 (ref) 0.82 (0.59, 1.15) 0.99 (0.71, 1.38) 0.003
Hazard ratios (HR) and 95% conﬁdence intervals were derived from Cox proportional hazards regression models.
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; PTH, parathyroid hormone; UAE, urinary albumin excretion.
aDerived from a Cox proportional hazards model by using urinary calcium excretion as a continuous linear term.
bDerived by using the likelihood ratio test, comparing nested Cox proportional hazards regression models with a linear or linear and cubic spline terms.
cModel 1: Adjusted for age, sex, height, weight, race, baseline eGFR, and baseline lnUAE.
dModel 2: Model 1 þ smoking, alcohol, hypertension, diabetes, parental history of CKD, and hypercholesterolemia.
eModel 3: Model 2 þ plasma magnesium, calcium, phosphorus, PTH and 1,25-dihydroxyvitamin D, albumin, and use of loop diuretics, thiazide diuretics, calcium supplements, vitamin D supplements, and bisphosphonates.


















































Figure 2. Associations between UCaE and risk of chronic kidney disease in 5491 subjects of the Prevention of Renal and Vascular End-Stage
Disease (PREVEND) study. Data were ﬁt by time-dependent Cox proportional hazards regression models based on restricted cubic splines with
3 knots and adjusted for the covariates in model 1 (a, c, e) and model 4 (b, d, f). The 2 upper panels represent the associations between UCaE
and risk of CKD deﬁned as eGFRcreatinine-cystatin C < 60 ml/min per 1.73 m2 and/or UAE > 30 mg/24 h (a, b). The 2 middle panels represent the
associations between UCaE and risk of CKD defined as eGFRcreatinine-cystatin C < 60 ml/min per 1.73 m2 alone (c, d). The 2 lower (continued)
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Table 3. Association of urinary calcium excretion and decline in eGFR (ml/min/1.73m2) per year in 6531 subjects of the Prevention of Renal and
Vascular End-Stage Disease (PREVEND) study
Variable
Unadjusted Multivariable adjustment
Crude model Model 1a Model 2b Model 3c Model 4d
b P value b P value b P value b P value b P value
UCaE 0.035 (0.011, 0.059) 0.01 0.075 (0.052, 0.099) <0.001 0.084 (0.057, 0.111) <0.001 0.069 (0.035, 0.101) <0.001 0.072 (0.031, 0.112) <0.001
Beta is expressed per 1 SD increase for continuous variables and versus the reference category for dichotomous variables. 95% CI are in parentheses.
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; PTH, parathyroid hormone; UAE, urinary albumin excretion; UCa, urinary calcium excretion.
aModel 1: Adjusted for age, sex, height, weight, race, baseline eGFR, and baseline lnUAE.
bModel 2: Model 1 þ smoking, alcohol, hypertension, diabetes, parental history of CKD, and hypercholesterolemia.
cModel 3: Model 2 þ plasma magnesium, calcium, phosphorus, PTH and 1,25-dihydroxyvitamin D, albumin, and use of loop diuretics, thiazide diuretics, calcium supplements, vitamin D
supplements, and bisphosphonates.
dModel 4: Model 3 þ urinary sodium, potassium, urea, and magnesium excretion.
=
JM Taylor et al.: Urinary Calcium Excretion and CKD CLINICAL RESEARCHAssociation Between UCaE and Mortality and
Cardiovascular Events
Lastly, because low UCaE may reﬂect poor dietary
intake associated with impaired general health, we also
studied the association between UCaE and all-cause
mortality and cardiovascular events. No such associa-
tions were observed (Table 6). In particular, those in
the lowest quintile of UCaE did not have a signiﬁcantly
increased risk of all-cause mortality (HR: 1.17 [0.68–
2.01], P ¼ 0.57) or cardiovascular events (HR: 0.98
[0.66–1.45], P ¼ 0.92) in the ﬁnal (or any) model.
DISCUSSION
The ﬁndings from this study indicate that, in a
population-based cohort, having a higher UCaE was not
associated with an increased risk of CKD. Surprisingly,
lower UCaE was associated with a higher risk of inci-
dent CKD. When CKD was deﬁned only by eGFR, a
signiﬁcant linear trend was present, with every 1
mmol/24 h increase in UCaE being associated with an
11% lower risk of incident CKD during follow-up.
When CKD was deﬁned by both eGFR and UAE, or
only by UAE, signiﬁcant nonlinear trends were
observed, with the lowest quintiles of UCaE having the
highest risk of CKD during follow-up. Alternative
endpoint analyses and sensitivity analyses conﬁrmed
the robustness of these ﬁndings.
It has been shown that speciﬁc renal tubular diseases
that result in hypercalciuria lead to nephrocalcinosis
and accelerated renal function loss.5–8 These ﬁndings
suggest that high UCaE may have deleterious renal
effects. Although many regulatory factors may affect
calcium uptake and excretion, increasing dietary intake
will give rise to UCaE, which has the potential to be
harmful to kidney tissue. Because less than 50% of the
population meet their recommended intake for calciumFigure 2. (continued) panels represent the associations between UCaE a
indicate the 95% confidence intervals (CIs). The spline curve is truncated
standard for UCaE was 3.82 mmol/24 h. P values for nonlinear association a
P ¼ 0.02 for (e), and P ¼ 0.003 for (f). CKD, chronic kidney disease; eGFR
hazard ratio; UAE, urinary albumin excretion; UCaE, urinary calcium excre
Kidney International Reports (2017) 2, 366–379and are at risk for fractures, supplementation to
increase calcium intake for the beneﬁts of improving
bone health seems logical.1–3,24 However, a recent
systematic review and meta-analysis concluded that,
although increasing calcium intake may result in small
increases in bone mineral density, it is unlikely to be
clinically meaningful for the reduction of bone frac-
tures.4 Given that no beneﬁt was observed in reducing
bone fractures, consuming high amounts of calcium
may ultimately pose more of a risk than a beneﬁt.
Surprisingly, studies examining the effects of UCaE on
the kidneys have focused on the risk for kidney stones,
and did not report on kidney function outcome. This
makes our study the ﬁrst to examine the effects of UCaE
on long-term kidney function in the general
population.
Interestingly, in this cohort of community-dwelling
adults, we found that high UCaE did not result in an
increased risk of developing CKD. It should be noted
that the studies demonstrating the effects of calcium
intake on the development of kidney stones have pri-
marily included individuals taking calcium and/or
vitamin D supplements.9,25 In our cohort, only 0.6% of
individuals (31/4671) were reported to be on calcium
supplementation, and even fewer were on vitamin D.
We also observed lower mean UCaE than other epide-
miological studies that have shown adverse renal
events in individuals with high UCaE (Nurses’ Health
Study I, Nurses’ Health Study II, and the Health Pro-
fessionals Follow-up Study, 4.02 mmol/24 h compared
with 4.90, 5.30, 4.96 mmol/24 h, respectively).9 Both
the low rate of individuals on supplements and lower
UCaE compared with previous epidemiologic cohorts
may have hindered the ability to ﬁnd an association
between increasing risk of CKD and higher UCaE.
However, it may also be that increasing intake ofnd risk of CKD defined as UAE > 30 mg/24 h (e, f). The gray areas
at the 0.5th and 99.5th percentile of the distribution curve. Reference
re P ¼ 0.01 for (a), P ¼ 0.004 for (b), P ¼ 0.85 for (c), P ¼ 0.90 for (d),
, estimated glomerular filtration rate; maHR, multivariable adjusted
tion.
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Table 4. Association between urinary calcium excretion and risk of being a fast progressor in 6531 subjects of the Prevention of Renal and
Vascular End-Stage Disease (PREVEND) study
Outcome
Continuous urinary calcium
excretion, per 1 mmol/24 h
increment Ptrend lineara
Sex-speciﬁc quintiles of urinary calcium excretion, mmol/24 h
_ <2.57 2.57--3.60 3.61--4.58 4.59--5.84 >5.84
\ <2.12 2.12--3.05 3.05--3.99 3.99--5.17 >5.17
N 6531 1304 1309 1307 1305 1306
Risk of being a fast progressor
Number of fast progressors 1306 307 281 228 251 239
Crude model 0.95 (0.92, 0.98) 0.001 1.46 (1.20, 1.77) 1.29 (1.07, 1.57) 1.00 (ref) 1.13 (0.92, 1.37) 1.06 (0.87, 1.30)
Model 1b 0.92 (0.89, 0.96) <0.001 1.42 (1.15, 1.75) 1.37 (1.11, 1.69) 1.00 (ref) 1.12 (0.90, 1.38) 0.89 (0.72, 1.11)
Model 2c 0.92 (0.89, 0.96) <0.001 1.38 (1.11, 1.71) 1.38 (1.11, 1.70) 1.00 (ref) 1.11 (0.89, 1.38) 0.87 (0.70, 1.09)
Model 3d 0.94 (0.89, 0.98) 0.01 1.39 (1.05, 1.83) 1.40 (1.07, 1.83) 1.00 (ref) 1.14 (0.86, 1.51) 0.92 (0.69, 1.22)
Model 4e 0.92 (0.87, 0.97) 0.003 1.43 (1.07, 1.91) 1.42 (1.08, 1.86) 1.00 (ref) 1.12 (0.84, 1.48) 0.86 (0.64, 1.16)
Odds ratios (OR) and 95% conﬁdence intervals were derived from logistic regression models.
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; PTH, parathyroid hormone; UAE, urinary albumin excretion.
aDerived from a logistic regression model by using urinary calcium excretion as a continuous term.
bModel 1: Adjusted for age, sex, height, weight, race, baseline eGFR, and baseline lnUAE.
cModel 2: Model 1 þ smoking, alcohol, hypertension, diabetes, parental history of CKD, and hypercholesterolemia.
dModel 3: Model 2 þ plasma magnesium, calcium, phosphorus, PTH and 1,25-dihydroxyvitamin D, albumin, and use of loop diuretics, thiazide diuretics, calcium supplements, vitamin D
supplements, and bisphosphonates.
eModel 4: Model 3 þ urinary sodium, potassium, urea, and magnesium excretion.
CLINICAL RESEARCH JM Taylor et al.: Urinary Calcium Excretion and CKDcalcium through supplementation poses more of a risk
to the kidney than if done so through dietary sources.
This may be because some calcium supplements have
been shown to also include contaminants (such as lead)
that may be damaging the kidney, or it may be due to
the fact that calcium-rich foods also contain additional
nutrients and bioactive food components that may alter
the absorption or utilization of calcium, making the
risk associated with these two sources of calcium
potentially different from one another.26
Unexpectedly, low UCaE resulted in an increased
risk of developing CKD. It has been suggested that low
excretion of nutrients (i.e., poor nutritional status) may
be a reﬂection of individuals in poor health. We
therefore examined the association between UCaE andTable 5. Association between urinary calcium excretion and risk of having
of Renal and Vascular End-Stage Disease (PREVEND) study
Outcome
Continuous urinary calcium





N 6531 1304 1
Risk of $25% decline in kidney function
Person-years 59,406 11,275 11
Number of events 549 145
Crude model 0.92 (0.88, 0.97) <0.001 1.77 (1.36, 2.30) 1.40 (1
Model 1c 0.92 (0.88, 0.96) <0.001 1.63 (1.24, 2.14) 1.45 (1
Model 2d 0.92 (0.87, 0.96) <0.001 1.64 (1.24, 2.17) 1.48 (1
Model 3e 0.91 (0.86, 0.97) 0.01 1.65 (1.13, 2.42) 1.68 (1
Model 4f 0.91 (0.84, 0.99) 0.02 1.71 (1.14, 2.56) 1.72 (1
Hazard ratios (HR) and 95% conﬁdence intervals were derived from Cox proportional hazards
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; PTH, parathyroid horm
aDerived from a Cox proportional hazards model by using urinary calcium excretion as a cont
bDerived by using the likelihood ratio test, comparing nested Cox proportional hazards regres
cModel 1: Adjusted for age, sex, height, weight, race, baseline eGFR, and baseline lnUAE.
dModel 2: Model 1 þ smoking, alcohol, hypertension, diabetes, parental history of CKD, hyper
eModel 3: Model 2 þ plasma magnesium, calcium, phosphorus, PTH and 1,25-dihydroxyvitamin
supplements, and bisphosphonates.
fModel 4: Model 3 þ urinary sodium, potassium, urea, and magnesium excretion.
376risk of all-cause mortality and cardiovascular events.
We found no association with all-cause mortality or
cardiovascular events, including no association in the
low UCaE range. This suggests that these ﬁndings are
not related to the fact that those subjects in the lowest
quintile of UCaE are in poor overall health. Unfortu-
nately, given the observational nature of this study, it
is not possible to determine the mechanism(s) by which
low UCaE leads to CKD. Hypothetically, it may be that
increases in parathyroid hormone (resulting from low
plasma calcium) have deleterious renal effects, for
instance, by the PTH-induced epithelial-mesenchymal
transition leading to ﬁbrosis.27,28 However, even after
adjusting for PTH, UCaE was still associated with the
development of CKD in our analyses. The ﬁnding thata$25% decline in kidney function in 6531 subjects of the Prevention
quintiles of urinary calcium excretion, mmol/24 h
Ptrend nonlinearb
7--3.60 3.61--4.58 4.59--5.84 >5.84
2--3.05 3.05--3.99 3.99--5.17 >5.17
309 1307 1305 1306
,646 11,947 12,113 12,425
119 90 85 110
.06, 1.84) 1.00 (ref) 0.92 (0.68, 1.24) 1.14 (0.86, 1.50) <0.001
.10, 1.92) 1.00 (ref) 1.02 (0.76, 1.38) 1.00 (0.75, 1.32) 0.004
.11, 1.97) 1.00 (ref) 1.00 (0.74, 1.35) 0.99 (0.74, 1.33) 0.01
.14, 2.47) 1.00 (ref) 1.05 (0.69, 1.59) 0.91 (0.61, 1.36) 0.01
.17, 2.54) 1.00 (ref) 1.09 (0.71, 1.66) 0.90 (0.59, 1.38) 0.01
regression models.
one; UAE, urinary albumin excretion.
inuous linear term.
sion models with a linear or linear and cubic spline terms.
cholesterolemia, and history of cardiovascular events.
D, albumin, and use of loop diuretics, thiazide diuretics, calcium supplements, vitamin D
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Table 6. Association between urinary calcium excretion and risk of mortality in 5491 subjects of the Prevention of Renal and Vascular
End-Stage Disease (PREVEND) study
Outcome
Continuous urinary calcium
excretion, per 1 mmol/24 h
increment Ptrend lineara
Sex-speciﬁc quintiles of urinary calcium excretion, mmol/24 h
Ptrend nonlinearb
_ <2.65 2.65--3.67 3.68--4.58 4.59--5.80 >5.80
\ <2.16 2.16--3.08 3.09--4.00 4.01--5.14 >5.14
Mortality
Person-years 66,843 13,334 13,315 13,417 13,344 13,433
Number of events 267 63 62 45 52 45
Crude model 0.96 (0.90, 1.02) 0.19 1.41 (0.97, 2.07) 1.40 (0.95, 2.05) 1.00 (ref) 1.17 (0.78, 1.74) 1.00 (0.66, 1.51) 0.98
Model 1c 0.94 (0.88, 1.01) 0.09 1.36 (0.92, 2.01) 1.49 (1.01, 2.20) 1.00 (ref) 1.29 (0.86, 1.94) 0.99 (0.65, 1.50) 0.66
Model 2d 0.96 (0.89, 1.03) 0.28 1.42 (0.93, 2.17) 1.53 (1.00, 2.32) 1.00 (ref) 1.38 (0.89, 2.13) 1.15 (0.74, 1.80) 0.75
Model 3e 0.95 (0.87, 1.03) 0.21 1.26 (0.75, 2.11) 1.76 (1.08, 2.86) 1.00 (ref) 1.27 (0.75, 2.14) 1.06 (0.62, 1.82) 0.54
Model 4f 0.97 (0.87, 1.07) 0.52 1.17 (0.68, 2.01) 1.72 (1.05, 2.81) 1.00 (ref) 1.31 (0.78, 2.22) 1.14 (0.65, 2.00) 0.44
Cardiovascular event
Person-years 64,272 12,809 12,760 12,930 12,839 12,936
Number of events 448 98 93 92 84 81
Crude model 1.01 (0.96, 1.06) 0.72 1.08 (0.81, 1.43) 1.03 (0.77, 1.37) 1.00 (ref) 0.92 (0.68, 1.24) 0.88 (0.65, 1.18) 0.34
Model 1c 0.98 (0.93, 1.02) 0.32 0.98 (0.73, 1.30) 0.98 (0.73, 1.31) 1.00 (ref) 0.92 (0.68, 1.24) 0.80 (0.59, 1.09) 0.68
Model 2d 0.99 (0.94, 1.04) 0.69 1.05 (0.77, 1.43) 0.94 (0.69, 1.27) 1.00 (ref) 0.91 (0.67, 1.25) 0.91 (0.66, 1.25) 0.37
Model 3e 1.01 (0.95, 1.08) 0.69 1.01 (0.70, 1.47) 0.99 (0.69, 1.43) 1.00 (ref) 0.88 (0.60, 1.29) 0.98 (0.67, 1.42) 0.29
Model 4f 1.04 (0.96, 1.12) 0.31 0.98 (0.66, 1.45) 0.96 (0.67, 1.39) 1.00 (ref) 0.91 (0.62, 1.34) 1.04 (0.70, 1.54) 0.28
Hazard ratios (HR) and 95% conﬁdence intervals were derived from Cox proportional hazards regression models.
CKD, chronic kidney disease; eGFR, estimated glomerular ﬁltration rate; PTH, parathyroid hormone; UAE, urinary albumin excretion.
aDerived from a Cox proportional hazards model by using urinary calcium excretion as a continuous linear term.
bDerived by using the likelihood ratio test, comparing nested Cox proportional hazards regression models with a linear or linear and cubic spline terms.
cModel 1: Adjusted for age, sex, height, weight, race, baseline eGFR, and baseline lnUAE.
dModel 2: Model 1 þ smoking, alcohol, hypertension, diabetes, parental history of CKD, hypercholesterolemia, and history of cardiovascular events.
eModel 3: Model 2 þ plasma magnesium, calcium, phosphorus, PTH and 1,25-dihydroxyvitamin D, albumin, and use of loop diuretics, thiazide diuretics, calcium supplements, vitamin D
supplements, and bisphosphonates.
fModel 4: Model 3 þ urinary sodium, potassium, urea, and magnesium excretion.
JM Taylor et al.: Urinary Calcium Excretion and CKD CLINICAL RESEARCHlow UCaE increases risk of developing CKD needs
conﬁrmation and further study.
Importantly, our ﬁndings were conﬁrmed by
various sensitivity analyses. First, we found similar
outcomes when using a buffer by removing individuals
with the lowest baseline eGFR (60–66 ml/min per 1.73
m2) and highest baseline UAE (25–30 mg/24 h). Second,
we also found similar trends when adjusting for the
oversampling of individuals with UAE$10 mg/l due to
the PREVEND study design. Third, an effect between
UCaE and decline in eGFR per year was observed.
Fourth, we found an inverse association between UCaE
and risk of being a fast progressor to CKD, deﬁned as
the 20% with the steepest decline in eGFR per year.
Finally, when CKD was deﬁned by having a $25%
decline in eGFR, we found that those in the lowest
quintile of UCaE had the highest risk of developing
CKD during follow-up. These ﬁndings support the
notion that low UCaE is associated with risk of CKD.
Limitations of this study should be considered. First,
while we controlled for many factors in the analyses,
residual confounding may still be possible as in all
epidemiological studies. Second, only 8.3% of the
population was classiﬁed as hypercalciuric (men: UCaE
>7.5 mmol/24 h, women: UCaE >6.2 mmol/24 h).29
This limits the ability to determine whether hyper-
calciuria may lead to an increased risk for CKD in the
future. However, even in this subgroup, no increasedKidney International Reports (2017) 2, 366–379risk for incident CKD was found. Third, these results
may not be generalizable to all races because >95% of
the PREVEND cohort is Caucasian. Lastly, the PRE-
VEND cohort oversampled individuals with elevated
UAE. However, subjects with elevated albuminuria at
baseline were excluded from these analyses, and when
we additionally adjusted for sample design in one of
the sensitivity analyses this rendered similar trends.
Strengths of this study include that it is the ﬁrst
study to examine the associations of UCaE with risk of
CKD in a population-based cohort, along with this
study being conducted prospectively, collecting mul-
tiple 24-hour urine samples, and having a relatively
large sample size. We also used a CKD endpoint that
consisted of a creatinine-cystatin C-based eGFR and 2
consecutive 24-hour UAE at each time point to deter-
mine CKD events. Lastly, several sensitivity analyses
(some using alternative endpoints, such as decline in
eGFR per year, risk of being a fast progressor to CKD,
and risk of having a $25% decline in kidney function
during follow-up) were performed to conﬁrm our
ﬁndings.
In conclusion, low UCaE, rather than high UCaE,
was associated with an increased risk of developing
CKD in this prospective, population-based cohort
study. This effect remained even after adjustment for
various confounders. Although the effect of increasing
calcium intake on bone health may be in question, one377
CLINICAL RESEARCH JM Taylor et al.: Urinary Calcium Excretion and CKDmodiﬁable factor that may be renoprotective is the
avoidance of low UCaE.
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